ArticleScientific reports2024
A deep learning-based ADRPPA algorithm for the prediction of diabetic retinopathy progression.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A gated task-attentive multi-task network for unified retinal image analysis.Scientific reports · 2026Article
- The Role of Artificial Intelligence in the Diagnosis and Management of Diabetic Retinopathy.Journal of clinical medicine · 2025Review
- Review
- Artificial intelligence applied to diabetes complications: a bibliometric analysis.Frontiers in artificial intelligence · 2025Article
- Artificial intelligence in proliferative diabetic retinopathy: advancing diagnosis, precision surgery, and anti-VEGF therapy optimization.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As an alternative to assessments performed by human experts, artificial intelligence (AI) is currently being used for screening fundus images and monitoring diabetic retinopathy (DR). Although AI models can provide quasi-clinician diagnoses, they rarely offer new insights to assist clinicians in predicting disease prognosis and treatment response. Using longitudinal retinal imaging data, we developed and validated a predictive model for DR progression: AI-driven Diabetic Retinopathy Progression Prediction Algorithm (ADRPPA). In this retrospective study, we analyzed paired retinal fundus images of the same eye captured at ≥ 1-year intervals. The analysis was performed using the EyePACS dataset. By analyzing 12,768 images from 6384 eyes (2 images/eye, taken 733 ± 353 days apart), each annotated with DR severity grades, we trained the neural network ResNeXt to automatically determine DR severity. EyePACS data corresponding to 5108 (80%), 639 (10%), and 637 (10%) eyes were used for model training, validation, and testing, respectively. We further used an independent e-ophtha dataset comprising 148 images annotated with microaneurysms, 118 (75%) and 30 (25%) of which were used for training and validation, respectively. This dataset was used to train the neural network Mask Region-based Convolutional Neural Network (Mask-RCNN) for quantifying microaneurysms. The DR and microaneurysm scores from the first nonreferable DR (NRDR) image of each eye were used to predict progression to referable DR (RDR) in the second image. The area under the receiver operating characteristic curve values indicating our model's performance in diagnosing RDR were 0.963, 0.970, 0.968, and 0.971 for the trained ResNeXt models with input image resolutions of 256 × 256, 512 × 512, 768 × 768, and 1024 × 1024 pixels, respectively. In the validation of the Mask-RCNN model trained on the e-ophtha dataset resized to 1600 pixels in height, the recall, precision, and F1-score values for detecting individual microaneurysms were 0.786, 0.615, and 0.690, respectively. The best model combination for predicting NRDR-to-RDR progression included the 768-pixel ResNeXt and 1600-pixel Mask-RCNN models; this combination achieved recall, precision, and F1-scores of 0.338 (95% confidence interval [CI]: 0.228-0.451), 0.561 (95% CI: 0.405-0.714), and 0.422 (95% CI: 0.299-0.532), respectively. Thus, deep learning models can be trained on longitudinal retinal imaging data to predict NRDR-to-RDR progression. Furthermore, DR and microaneurysm scores generated from low- and high-resolution fundus images, respectively, can help identify patients at a high risk of NRDR, facilitating timely treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.